Xenon Pharmaceuticals Inc. (NASDAQ: XENE) presented data from its Phase 3 X-TOLE2 study of azetukalner for focal onset seizures at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE